



Cleave Biosciences Raises Additional \$2 Million in Series A Financing

Osage University Partners Tops Off Series A Financing at \$44 Million

SAN FRANCISCO, Calif., November 15, 2011—Cleave Biosciences has raised an additional \$2 million in Series A financing from Osage University Partners, a new investor. [Osage University Partners](#) joins previous Series A investors [U.S. Venture Partners](#), [5AM Ventures](#), [Clarus Ventures](#), [OrbiMed Advisors](#) and [Astellas Venture Management](#) to fund a total of \$44 million for the newly established biopharmaceutical company's cancer drug discovery and development. Cleave Biosciences is currently conducting lead identification and optimization for multiple small molecule programs in the area of protein homeostasis.

Osage University Partners is a venture capital fund that partners with select academic institutions to serve as their co-investment vehicle in start-ups that are licensing university technologies. Cleave Biosciences has licensed technology from the laboratory of Raymond Deshaies, Ph.D., Professor and Executive Officer of Biology at the California Institute of Technology, which is one of the partners of Osage University Partners. Dr. Deshaies is a world-renowned expert in the study of protein degradation pathways. Dr. Deshaies is Scientific Co-Founder of Cleave and acts as advisor to the company.

###

Contacts:

Laura Shawver, Ph.D.
Chief Executive Officer
Cleave Biosciences
(650) 443-3010
lshawver@cleavebio.com

Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com